ZA954990B - Interleukin-5 specific recombinant antibodies - Google Patents

Interleukin-5 specific recombinant antibodies

Info

Publication number
ZA954990B
ZA954990B ZA954990A ZA954990A ZA954990B ZA 954990 B ZA954990 B ZA 954990B ZA 954990 A ZA954990 A ZA 954990A ZA 954990 A ZA954990 A ZA 954990A ZA 954990 B ZA954990 B ZA 954990B
Authority
ZA
South Africa
Prior art keywords
interleukin
recombinant antibodies
specific recombinant
specific
heavy
Prior art date
Application number
ZA954990A
Other languages
English (en)
Inventor
Mark William Bodmer
Diljeet Singh Athwal
John Spencer Emtage
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of ZA954990B publication Critical patent/ZA954990B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA954990A 1994-06-17 1995-06-15 Interleukin-5 specific recombinant antibodies ZA954990B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies

Publications (1)

Publication Number Publication Date
ZA954990B true ZA954990B (en) 1996-12-17

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954990A ZA954990B (en) 1994-06-17 1995-06-15 Interleukin-5 specific recombinant antibodies

Country Status (18)

Country Link
US (3) US5998586A (cs)
EP (1) EP0765392B1 (cs)
JP (1) JP3973682B2 (cs)
AT (1) ATE264389T1 (cs)
AU (1) AU694783B2 (cs)
CA (1) CA2192543C (cs)
CZ (1) CZ292295B6 (cs)
DE (1) DE69532889T2 (cs)
ES (1) ES2218546T3 (cs)
FI (1) FI965032A (cs)
GB (1) GB9412230D0 (cs)
HU (1) HU221641B1 (cs)
IL (1) IL114179A (cs)
NO (1) NO964808L (cs)
NZ (1) NZ287927A (cs)
SK (1) SK282625B6 (cs)
WO (1) WO1995035375A1 (cs)
ZA (1) ZA954990B (cs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5683892A (en) 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
DE69535319T2 (de) * 1994-12-23 2007-07-19 Smithkline Beecham Corp. Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
EP1173573A1 (en) * 1999-04-23 2002-01-23 Pharmexa A/S Method for down-regulating il5 activity
NZ572565A (en) 2006-05-25 2011-04-29 Glaxo Group Ltd Modified humanised anti-interleukin-18 antibodies
MX2010010667A (es) 2008-03-28 2010-11-09 Glaxosmithkline Llc Metodos de tratamiento.
US10421819B2 (en) * 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
US9505826B2 (en) * 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (en) 2011-10-03 2021-12-01 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
AU2013370467B2 (en) * 2012-12-26 2018-10-04 Oncosynergy, Inc. Anti- integrin beta1 antibody compositions and methods of use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3160479A4 (en) * 2014-06-30 2018-07-04 Academia Sinica Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
CN107660213B (zh) 2015-02-10 2023-01-13 米纳瓦生物技术公司 人源化抗MUCl＊抗体
CN116327921A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权（第2 号）有限公司 生物医药组合物
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
EP3689906A4 (en) 2017-09-29 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. IL-5 ANTIBODIES, ANTIGIBINDING FRAGMENT THEREOF, AND MEDICAL USES THEREOF
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
WO2020200099A1 (zh) 2019-03-29 2020-10-08 江苏恒瑞医药股份有限公司 包含抗il-5抗体的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR960002183B1 (ko) * 1988-11-03 1996-02-13 쉐링 코포레이션 호산구증다증 억제또는 경감을 위한 약제학적 조성물
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
AU683836B2 (en) * 1992-02-06 1997-11-27 Schering Corporation Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
AU684041B2 (en) * 1992-02-19 1997-12-04 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
EP0765392B1 (en) 2004-04-14
HU9603183D0 (en) 1997-01-28
CA2192543C (en) 2008-07-29
US6316227B1 (en) 2001-11-13
SK160096A3 (en) 1997-06-04
AU694783B2 (en) 1998-07-30
FI965032A0 (fi) 1996-12-16
CA2192543A1 (en) 1995-12-28
ES2218546T3 (es) 2004-11-16
US6734286B2 (en) 2004-05-11
EP0765392A1 (en) 1997-04-02
ATE264389T1 (de) 2004-04-15
GB9412230D0 (en) 1994-08-10
NO964808D0 (no) 1996-11-13
NO964808L (no) 1997-02-17
AU2680395A (en) 1996-01-15
IL114179A0 (en) 1995-10-31
CZ292295B6 (cs) 2003-08-13
US20020042089A1 (en) 2002-04-11
WO1995035375A1 (en) 1995-12-28
CZ371296A3 (cs) 1998-05-13
US5998586A (en) 1999-12-07
DE69532889D1 (de) 2004-05-19
NZ287927A (en) 1998-07-28
SK282625B6 (sk) 2002-10-08
DE69532889T2 (de) 2005-03-10
JP3973682B2 (ja) 2007-09-12
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
JPH10501697A (ja) 1998-02-17
IL114179A (en) 2001-08-26
FI965032A (fi) 1996-12-16

Similar Documents

Publication Publication Date Title
HUT76672A (en) Interleukin-5 specific recombinant antibodies
FI956112A0 (fi) Monoklonaalinen anti- V-integriinivasta-aine
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
AU1289795A (en) Monoclonal antibodies specific for human interleukin-5
EP0870826A4 (en) NEW PROTEINS AND MONOCLONAL ANTIBODIES AGAINST THESE
HUP9904620A3 (en) Purified sperm surface antigen,monoclonal antibody therefor and applications therefor
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
EP0578515A3 (en) Humanized monoclonal antibodies.
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU6031090A (en) Monoclonal antibodies against a tumor-associated antigen
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
EP0554458A4 (en) Immunoassay, monoclonal antibody and hybridoma
AU8547291A (en) Monoclonal antibodies against tenascin
EP0654532A4 (en) ANTIMUCOGLYCOPROTEIN MONOCLONAL ANTIBODIES.
AU5449390A (en) Monoclonal antibody against c-reactive protein
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
AU2002300457A1 (en) Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
EP0668923A4 (en) MONOCLONAL ANTIBODY.
FI960566A0 (fi) Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
BR1100555B1 (pt) anticorpos monoclonais humanizados.
IE901956L (en) Monoclonal antibody.
GB9212074D0 (en) Monoclonal antibody
AU4283793A (en) Monocyte adhesion protein and monoclonal antibody thereto
IE901210L (en) Monoclonal antibody